Sequencing Therapies for Metastatic Renal Cell Carcinoma.
Sequencing Therapies for Metastatic Renal Cell Carcinoma.
Urol Clin North Am. 2020 Aug;47(3):305-318
Authors: Dizman N, Arslan ZE, Feng M, Pal SK
Abstract
In an era of several therapeutic options available, optimal treatment sequencing is crucial to providing patients the most effective therapy and promoting quality of life. In clear cell renal cell carcinoma, a combination approach with an immunotherapy backbone, such as nivolumab/ipilimumab or axitinib/pembrolizumab, has a key role in the first-line setting. Safety and activity data support the transition to single-agent targeted therapies in the second-line setting. Nivolumab monotherapy possesses clinical and mechanistic rationale as a second-line therapeutic option for patients treated with targeted therapies in the first-line setting. Gene expression models are being generated from large prospective clinical trial data sets.
PMID: 32600533 [PubMed - in process]
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Dizman N, Arslan ZE, Feng M, Pal SK Tags: Urol Clin North Am Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Genetics | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology | Yervoy